Diabetes economic burden is among the largest single-disease cost categories in the United States. Combined direct medical and indirect costs now exceed $400 billion per year, and the trajectory has been upward for two decades. Understanding what drives this burden — hospital care, medications, lost work, disability, and premature mortality — helps families, employers, and policymakers see where prevention and access investments produce the largest returns.
The National Cost Picture
- Direct medical costs include hospital care, outpatient visits, prescriptions, supplies, equipment, and long-term care
- Indirect costs include lost workdays, reduced productivity at work, disability, and premature death
- The American Diabetes Association’s national estimate combines both and places the total above $400 billion annually
- Roughly three-quarters of the total is direct medical spending; the remainder is indirect
- Cost has grown at a faster pace than overall U.S. health spending in many years
- Approximately 1 of every 4 healthcare dollars in the United States goes to people with diabetes
Where Direct Medical Spending Goes
| Category | Approximate Share of Direct Costs |
|---|---|
| Hospital inpatient care | About 30 percent |
| Prescription medications (including insulin and supplies) | About 30 percent |
| Outpatient visits and procedures | About 15 percent |
| Long-term care and nursing facility | About 10 percent |
| Emergency department visits | Smaller but rising share |
| Diabetes supplies (meters, strips, CGM, syringes) | Smaller but rising share |
Per-Person Spending Patterns
- Adults with diabetes have medical spending roughly 2.3 times higher than peers without diabetes
- Type 1 diabetes typically costs more per person than type 2, mainly due to insulin, CGM, and pump expenses
- Complications dramatically raise per-person costs — cardiovascular disease, kidney disease, and amputation each add tens of thousands of dollars per event
- People newly started on a GLP-1 receptor agonist or SGLT2 inhibitor often see medication spending double or triple in the first year
- Adults over 65 generally have higher overall spending but lower out-of-pocket spending due to Medicare
Out-of-Pocket Reality
- Average out-of-pocket spending for adults with diabetes is roughly $2,000 to $2,500 per year
- Insulin users on commercial plans without caps could spend $1,000 to $4,000 or more per year on insulin alone before recent reforms
- The Medicare Part D $35 per month insulin cap (effective in 2023) has substantially reduced out-of-pocket spending for older adults
- Several states have adopted $35 to $100 per month commercial insulin caps
- GLP-1 receptor agonists frequently cost $1,000 to $1,400 per month at retail, with savings cards reducing costs for eligible patients
- High-deductible health plans expose patients to early-year cost spikes for medications and supplies
Indirect Costs
- Reduced labor force participation — workers with diabetes and complications retire or leave the workforce earlier
- Absenteeism — more sick days due to diabetes management and complications
- Presenteeism — reduced productivity while at work
- Permanent and temporary disability claims
- Premature mortality — value of years of life lost
- Family caregiving costs, including unpaid time and lost wages
Drug Class Pricing Snapshot
| Class | Typical Monthly List Price Range |
|---|---|
| Metformin (generic) | About $4 to $20 |
| Sulfonylureas (glipizide, glimepiride, generic) | About $4 to $20 |
| DPP-4 inhibitors (sitagliptin and others) | About $500 to $700 |
| SGLT2 inhibitors (empagliflozin, dapagliflozin) | About $500 to $700 |
| GLP-1 receptor agonists (semaglutide, dulaglutide, liraglutide) | About $900 to $1,400 |
| Insulin analogs (varies by formulation) | About $200 to $1,500 depending on dose and plan |
| Tirzepatide | About $1,000 to $1,200 |
Hospital and Complication Costs
- Hospital stays for diabetes-related conditions account for a substantial share of total inpatient spending
- DKA hospitalizations alone cost the system several billion dollars per year
- Lower-limb amputation related to diabetes adds significant inpatient, surgical, rehabilitation, and prosthetic costs
- End-stage kidney disease treatment, particularly dialysis, is among the most expensive sustained therapies in healthcare
- Hospital readmissions within 30 days are common after diabetes-related admissions and are a key cost target for hospitals
Insurance and Coverage
- Medicare covers roughly one-third of adults with diabetes; Medicaid and commercial insurance cover most others
- Public payers carry a large share of total diabetes spending
- Medicare Part B covers diabetes supplies and DSMES; Part D covers most diabetes medications
- Medicaid coverage for CGM, GLP-1 RA, and DSMES varies by state
- Uninsured adults face significantly higher mortality and complication rates
- Community health centers and 340B pharmacy programs reduce costs for many low-income patients
Policy Levers
- Inflation Reduction Act insulin caps and Part D out-of-pocket spending caps
- State-level commercial insulin caps
- Medicare Medication Therapy Management for high-cost users
- Medicaid expansion in remaining states
- National DPP and DSMES reimbursement
- Special Diabetes Program for Indians funding renewal
- Pharmacy benefit manager transparency reform
- Biosimilar insulin uptake and interchangeable substitution rules
- Coverage parity for telehealth diabetes services
Where Prevention Saves Money
- Each prevented case of type 2 diabetes avoids decades of medication, supply, and complication spending
- DPP participation costs are typically a small fraction of one year of diabetes care
- Foot care and ulcer prevention dramatically reduce amputation costs
- Eye exam adherence reduces severe vision loss and related disability
- Tight blood pressure and lipid control reduce hospital admissions
- Smoking cessation has cardiovascular cost benefits within 1 to 2 years
Related Reading
See our companion articles on diabetes statistics by state, diabetes mortality trends, and our overview of prediabetes basics.
The Bottom Line
Diabetes economic burden in the United States exceeds $400 billion per year when medical and indirect costs are combined. Hospital care, prescriptions, lost productivity, and disability are the largest drivers, with per-person spending roughly 2.3 times that of people without diabetes. Recent policy changes have reduced out-of-pocket insulin spending for many patients, but GLP-1 receptor agonist pricing, complication-related hospitalizations, and uneven coverage across states keep the overall burden high. Prevention, early access to evidence-based therapy, and steady investment in primary care produce the largest long-term cost savings.
